Put companies on watchlist
M1 Kliniken AG
ISIN: DE000A0STSQ8
WKN: A0STSQ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

M1 Kliniken AG · ISIN: DE000A0STSQ8 · EQS - Company News (68 News)
Country: Germany · Primary market: Germany · EQS NID: 1830421
05 February 2024 01:00PM

Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard


EQS-News: M1 Kliniken AG / Key word(s): Investment
Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard

05.02.2024 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


The two members of the Management Board of M1 Kliniken AG, Mr Attila Strauss and Mr Kilian Brenske, acquired a total of 1.5 million shares in the company from MPH Health Care AG on 2 February 2024. The Co-CEOs justify the share purchase with their confidence in the long-term growth prospects of M1 Kliniken AG and the desire to participate even more strongly in the strategic direction and development of the company.
 
Co-CEO Kilian Brenske explains: "We are firmly convinced that our investment will further strengthen investor confidence. The profitable growth of our group of companies remains the focus of our actions." Co-CEO, Attila Strauss, adds: "Intensifying communication with external investors, a shareholder-friendly dividend policy and also a possible uplisting to the Prime Standard will be further focal points."

About M1 Kliniken AG: M1 Kliniken AG is the leading fully integrated provider of aesthetic medical health services in Europe. In the aesthetic and surgical fields, the group offers products and services with the highest quality standards. Currently, under the brand "M1 Med Beauty," beauty medical treatments are offered at 59 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating rooms and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving internationalisation and is currently present in ten countries.
Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


05.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: ir@m1-kliniken.de
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1830421

 
End of News EQS News Service

1830421  05.02.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1830421&application_name=news&site_id=boersengefluester_html
Visual performance / price development - M1 Kliniken AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.